The Effect of SGLT2 Inhibitors on Symptomatic Functional Tricuspid Regurgitation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035120

Enrollment

150

Registered

2024-10-16

Start date

2024-11-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I07.1

Interventions

Group 1: Group with SGLT2 inhibitor: Participants are divided into two groups: the exposure group receives therapy with an SGLT2 inhibitor combined with a diuretic due to existing indications (heart f

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Severe functional tricuspid regurgitation Heart failure symptoms (NYHA = II, peripheral edema, ascites, pleural effusion, pulmonary edema, KCCQ = 50 points) Stable GDMT for at least six weeks Life expectancy > 12 months Signed informed consent

Exclusion criteria

Exclusion criteria: Severe mental disorders, drug/alcohol dependency Unstable patients (e.g., cardiogenic shock, severe cardiac decompensation) Patients with HFrEF Severe renal impairment (eGFR GOLD II Precapillary pulmonary hypertension (Group 1) Presence of an allergic reaction to SGLT2 inhibitors Type 1 diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Combined endpoint of absolute changes in KCCQ and corrected PISA-EROA after three months.	—

Secondary

Measure	Time frame
The secondary endpoints also include changes in the severity of TI, right ventricular function, physical capacity, and changes in NTproBNP levels.	—

Countries

Germany

Contacts

Public ContactCan Öztürk

Universitätsklinikum Bonn

can.oeztuerk@ukbonn.de+4022828715335

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026